The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Sheila A. Doggrell

Division of Health Practice

Auckland University of Technology

Northcote

Auckland

New Zealand

[email]@yahoo.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Health Practice, Auckland University of Technology, Northcote, Auckland, New Zealand. 2005 - 2006
  • School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia. 2003 - 2006
  • University of Queensland, School of Biomedical Sciences, Australia. 2004 - 2005
  • Department of Physiology and Pharmacology, The University of Queensland, Brisbane, Australia. 2001 - 2003
  • Cardiovascular Pharmacology Group, Faculty of Medicine and Health Sciences, The University of Auckland, New Zealand. 2001

References

  1. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Doggrell, S.A. Rev. Recent. Clin. Trials (2006) [Pubmed]
  2. Is exenatide advancing the treatment of type 2 diabetes?. Doggrell, S.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  3. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease. Doggrell, S.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  4. 'Simply stunning'--trastuzumab in HER2-positive breast cancer. Doggrell, S.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  5. Is amlodipine the best initial monotherapy for hypertension?. Doggrell, S.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  6. Pharmacology down under in 2005--focus on targets. Doggrell, S. Drug News Perspect. (2006) [Pubmed]
  7. Australian neuroscience in 2006--highlights from the scientific meeting. Doggrell, S.A. Drug News Perspect. (2006) [Pubmed]
  8. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  9. Fluoxetine--do the benefits outweigh the risks in adolescent major depression?. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  10. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  11. Recent advances in heart research. Doggrell, S.A. Drug News Perspect. (2005) [Pubmed]
  12. A small-molecule lead compound for the treatment of Alzheimer's disease. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  13. The safety of lumiracoxib when used in the treatment of arthritis. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  14. NF-kappa B--a target in the inflammation of bone destruction. Doggrell, S.A. Expert Opin. Ther. Targets (2005) [Pubmed]
  15. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Doggrell, S.A., Wanstall, J.C. Can. J. Physiol. Pharmacol. (2005) [Pubmed]
  16. CHARMed - the effects of candesartan in heart failure. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  17. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  18. Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper. Doggrell, S.A. Methods. Find. Exp. Clin. Pharmacol (2005) [Pubmed]
  19. Farnesoid X receptor agonism -- a new approach to the treatment of cholesterol gallstone disease. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  20. New targets and new drugs down under in 2004. Doggrell, S.A. Drug News Perspect. (2005) [Pubmed]
  21. Berberine--a novel approach to cholesterol lowering. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  22. Which drug combination for hormone-refractory prostate cancer?. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  23. Bradykinin B2 receptors--a target in diabetic nephropathy. Doggrell, S.A. Expert Opin. Ther. Targets (2005) [Pubmed]
  24. Recent important trials of pharmacotherapy in Parkinson's disease. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  25. Aspirin and esomeprazole are superior to clopidogrel in preventing recurrent ulcer bleeding. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  26. RITA--a small-molecule anticancer drug that targets p53. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  27. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Doggrell, S.A. Expert. Opin. Pharmacother (2005) [Pubmed]
  28. The nitrosterols--a step forward from the steroid anti-inflammatory drugs?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  29. New drugs being developed for the treatment of tuberculosis. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  30. Neuromedin U--a new target in obesity. Doggrell, S.A. Expert Opin. Ther. Targets (2005) [Pubmed]
  31. Stabilisation of calstabin2--a new approach in sudden cardiac death. Doggrell, S.A. Expert Opin. Ther. Targets (2005) [Pubmed]
  32. Phosphodiesterase 5A as a target in cardiac disease. Doggrell, S.A. Expert Opin. Ther. Targets (2005) [Pubmed]
  33. Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  34. The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  35. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Doggrell, S.A., Wanstall, J.C. Cardiovasc. Res. (2004) [Pubmed]
  36. Cytokines, signaling and diseases - a pharmacologist's view. Doggrell, S.A. Drug News Perspect. (2004) [Pubmed]
  37. Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  38. Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  39. Can food intake be reduced with peptide YY3-36?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  40. Amediplase. Menarini. Doggrell, S.A. Curr. Opin. Investig. Drugs (2004) [Pubmed]
  41. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  42. Dronedarone: an amiodarone analogue. Doggrell, S.A., Hancox, J.C. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  43. Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  44. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  45. Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  46. Recent important clinical trials of drugs in osteoporosis. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  47. New drugs for the prevention and treatment of migraine: topiramate and BIBN 4096 BS. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  48. Recent pharmacological advances in the treatment of preterm membrane rupture, labour and delivery. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  49. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  50. Atorvastatin versus pravastatin: intensive versus moderate lipid lowering. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  51. Is vasopressin-receptor antagonism an advancement in the treatment of heart failure?. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  52. Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage. Doggrell, S.A. Expert Opin. Ther. Targets (2004) [Pubmed]
  53. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  54. Telmisartan - killing two birds with one stone. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  55. Alpha-lipoic acid, an anti-obesity agent?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  56. Which drug combination for colorectal cancer?. Doggrell, S.A. Expert. Opin. Pharmacother (2004) [Pubmed]
  57. Calstabin2 - a new target in sudden cardiac death. Doggrell, S.A. Expert Opin. Ther. Targets (2004) [Pubmed]
  58. Focus on vascular pharmacology. Doggrell, S.A. Drug News Perspect. (2004) [Pubmed]
  59. New drugs and new targets. Doggrell, S.A. Drug News Perspect. (2004) [Pubmed]
  60. Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs?. Doggrell, S. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  61. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Doggrell, S.A. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  62. ACE inhibitors versus diuretics: ALLHAT versus ANBP2. Doggrell, S.A. Expert. Opin. Pharmacother (2003) [Pubmed]
  63. Is natalizumab a breakthrough in the treatment of multiple sclerosis?. Doggrell, S.A. Expert. Opin. Pharmacother (2003) [Pubmed]
  64. Does the melanin-concentrating hormone antagonist SNAP-7941 deserve 3As?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  65. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Doggrell, S.A. Expert. Opin. Pharmacother (2003) [Pubmed]
  66. Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters. Doggrell, S.A., Hancox, J.C. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  67. Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?. Doggrell, S. Expert. Opin. Pharmacother (2003) [Pubmed]
  68. Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?. Doggrell, S.A., Wanstall, J.C. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  69. Health and medical research down under in 2002. Doggrell, S.A. Drug News Perspect. (2003) [Pubmed]
  70. Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?. Doggrell, S. Expert. Opin. Pharmacother (2003) [Pubmed]
  71. Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth. Doggrell, S.A. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  72. Are implantable cardioverter-defribrillators always superior to amiodarone?. Doggrell, S.A. Expert. Opin. Pharmacother (2003) [Pubmed]
  73. Recurrent hope for the treatment of preterm delivery. Doggrell, S.A. Expert. Opin. Pharmacother (2003) [Pubmed]
  74. Cardiovascular research in Australia. Doggrell, S.A. Drug News Perspect. (2003) [Pubmed]
  75. Clopidogrel: a CURE in acute coronary syndromes?. Doggrell, S.A. Expert. Opin. Pharmacother (2002) [Pubmed]
  76. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. Doggrell, S.A. Expert. Opin. Pharmacother (2002) [Pubmed]
  77. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. Doggrell, S.A. Expert. Opin. Pharmacother (2002) [Pubmed]
  78. The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Doggrell, S.A. Expert. Opin. Investig. Drugs (2002) [Pubmed]
  79. Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2002) [Pubmed]
  80. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis. Doggrell, S.A. Expert. Opin. Pharmacother (2002) [Pubmed]
  81. Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect. Doggrell, S.A. Expert. Opin. Pharmacother (2002) [Pubmed]
  82. TACE inhibition: a new approach to treating inflammation. Doggrell, S.A. Expert. Opin. Investig. Drugs (2002) [Pubmed]
  83. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Doggrell, S.A. Expert. Opin. Investig. Drugs (2002) [Pubmed]
  84. Tedisamil: master switch of nature?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2001) [Pubmed]
  85. Potency, affinity constants and receptor reserves for noradrenaline and adrenaline on aortae from aged normo- and hypertensive rats. Doggrell, S.A., Chen, Y.Y. J. Pharm. Pharmacol. (2001) [Pubmed]
  86. The spironolactone renaissance. Doggrell, S.A., Brown, L. Expert. Opin. Investig. Drugs (2001) [Pubmed]
  87. Carvedilol versus other beta-blockers in heart failure. Doggrell, S.A. Expert. Opin. Investig. Drugs (2001) [Pubmed]
  88. ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure. Doggrell, S.A. Expert. Opin. Investig. Drugs (2001) [Pubmed]
  89. Triamcinolone: new and old indications. Doggrell, S.A. Expert. Opin. Pharmacother (2001) [Pubmed]
  90. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more. Doggrell, S.A. Expert. Opin. Pharmacother (2001) [Pubmed]
  91. ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET). Doggrell, S.A. Expert. Opin. Pharmacother (2001) [Pubmed]
  92. Responsiveness, affinity constants and receptor reserves for serotonin on aortae of aged normotensive and hypertensive rats. Doggrell, S.A., Chen, Y.Y. J. Pharm. Pharmacol. (2001) [Pubmed]
  93. Alteplase: descendancy in myocardial infarction, ascendancy in stroke. Doggrell, S.A. Expert. Opin. Investig. Drugs (2001) [Pubmed]
  94. A daughter of bradykinin that protects against septicaemia. Doggrell, S.A. Expert. Opin. Investig. Drugs (2001) [Pubmed]
  95. Pharmacotherapy of intermittent claudication. Doggrell, S.A. Expert. Opin. Pharmacother (2001) [Pubmed]
  96. Amiodarone -- waxed and waned and waxed again. Doggrell, S.A. Expert. Opin. Pharmacother (2001) [Pubmed]
  97. Using models in cardiovascular research: report on the satellite meeting to the International Congress of Physiological Sciences, Models in Cardiovascular Research. Doggrell, S.A., Chan, V. Methods. Find. Exp. Clin. Pharmacol (2001) [Pubmed]
  98. Bladder disease: A report based on the smooth muscle function in health and disease satellite meeting to the International Congress of Physiology. Doggrell, S.A. Drugs. Today (2001) [Pubmed]
  99. Targets to trials in diabetic complications. Doggrell, S.A. Drugs. Today (2001) [Pubmed]
  100. Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding?. Doggrell, S.A. Drugs. Today (2001) [Pubmed]
  101. Brain natriuretic peptide: Disease marker or more in cardiovascular medicine?. Doggrell, S.A. Drugs. Today (2001) [Pubmed]
 
WikiGenes - Universities